TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Terminated · Phase 2 · NCT05980598
Conditions: Head and Neck Neoplasms
At a glance
- Research payments reported, 2025
- $519,694
- U.S. investigators named
- 17
- Sites paid
- 19
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Ascendis Pharma A/S
- Tested
- TransCon TLR7/8 Agonist (drug), Pembrolizumab (drug), TransCon IL-2 β/γ (drug)
- Dates
- Started 2023-09-29; completion 2025-03-28
- Results posted
- Not yet
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years. This trial contains a safety run-in to evaluate the safety and tolerability of the two treatment arms: Arm A (TransCon TLR7/8 Agonist plus pembrolizumab) and Arm B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ). The safety run-i…
From ClinicalTrials.gov, last updated 2025-08-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ascendis Pharma Endocrinology Inc reported $519,694 in research payments for this study in 2025 (52 payments).
Products named: Yorvipath
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alain Algazi, M.D. Hematology & Oncology · San Francisco, CA
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Sagar Kansara, M.D. ENT (Otolaryngology) · San Francisco, CA
- Victoria M. Villaflor, M.D. Medical Oncology · Orange, CA
- Douglas E. Laux, MD Hematology & Oncology · Iowa City, IA
- Michael J. Jelinek, M.D. Medical Oncology · Chicago, IL
- Krishna A. Rao, M.D. Hematology & Oncology · Springfield, IL
- Daniel B. Vinh, M.D. ENT (Otolaryngology) · Indianapolis, IN
- Lori J. Wirth, MD Medical Oncology · Boston, MA
- Ammar Sukari, M.D. Medical Oncology · Detroit, MI
- Katharine A. Price, M.D. Medical Oncology · Rochester, MN
- Lukasz Czerwonka, M.D. Surgical Oncology · Stony Brook, NY
- Nashat Gabrail, M.D. Specialist · Canton, OH
- Nolan B. Seim, MD ENT (Otolaryngology) · Columbus, OH
- John M. Kaczmar, MD Medical Oncology · Charleston, SC
- Timothy J. Panella, M.D. Medical Oncology · Knoxville, TN
- Neil D. Gross, MD ENT (Otolaryngology) · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Medical University of South Carolina $145,492
- University of Iowa Hospital & Clinics, IA $50,770
- Gabrail Cancer Center Research LLC $43,692
- Mayo Clinic $43,130
- Research Foundation for The State University of New York $38,991
- Dana-Farber/mass General Brigham Cancer Care, Inc. $34,500
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $28,244
- University Health System, Inc, TN $25,914
- Karmanos Cancer Center, MI $23,219
- Board of Trustees of Southern Illinois University $20,630
- Ut MD Anderson Cancer Center $13,670
- Valkyrie Clinical Trials, Inc $9,560
- Dana-Farber Cancer Institute $8,850
- Our Lady of the Lake Regional Medical Center, LA $7,500
- The Ohio State University $6,325
- University of Louisville Research Foundation Inc $6,133
- Rush University Medical Center, IL $5,074
- City of Hope National Medical Ctr $5,000
- The Carl and Edyth Lindner Center $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.